Protara Therapeutics, Inc. (TARA)


-0.01 (-0.34%)
Symbol TARA
Price $2.94
Beta 1.545
Volume Avg. 0.04M
Market Cap 33.246M
Shares () -
52 Week Range 2.378-4.6
1y Target Est -
DCF Unlevered TARA DCF ->
DCF Levered TARA LDCF ->
ROE -48.95% Strong Sell
ROA -58.22% Strong Sell
Operating Margin -
Debt / Equity 10.98% Neutral
P/E -0.50 Neutral
P/B 0.32 Neutral


Consensus EPS

Upgrades & Downgrades

Latest TARA news

Mr. Jesse Shefferman
NASDAQ Global Market

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.